Added to YB: 2026-02-24
Pitch date: 2026-02-20
NKTR [neutral]
Nektar Therapeutics
+0.16%
current return
Author Info
No bio for this author
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
Market Cap
$2.1B
Pitch Price
$73.50
Price Target
140.00 (+90%)
Dividend
N/A
EV/EBITDA
-15.56
P/E
-9.33
EV/Sales
31.31
Sector
Pharmaceuticals
Category
growth
Updated thoughts/thesis on $NKTR
NKTR (update): IL-2 biologic for atopic dermatitis (AtD) & alopecia areata (AA). AtD: 27% EASI75 delta P2b, maintenance showed deepening responses + Q12W dosing matching Q4W. Targeting $50B+ market w/ differentiated MoA vs IL4/13 class. Clean safety, <1% DC due to ISRs. AA: Market mispriced at $0 despite proof of concept. Safe biologic will dominate JAKis (like Dupi vs Rinvoq in AtD: 2x less effective, 10x more sales). P3 efficacy likely improves w/ longer treatment + lower DC rates. Multiple $1B+ opportunities undervalued at $1.47B EV.
Read full article (70 min)